Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
26
Frequently Asked Questions
What is Market Cap of Trevi Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Trevi Therapeutics Inc market cap is $971.78M.
What is the 52-week high for Trevi Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Trevi Therapeutics Inc 52 week high is $9.92 as of September 18, 2025.
What is the 52-week low for Trevi Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Trevi Therapeutics Inc 52 week low is $2.36 as of September 18, 2025.
What is Trevi Therapeutics Inc stock price today?
Trevi Therapeutics Inc stock price today is $8.54.
What was Trevi Therapeutics Inc stock price yesterday?
Trevi Therapeutics Inc stock price yesterday was $7.98.
What is the PE ratio of Trevi Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Trevi Therapeutics Inc’s P/E ratio is -18.97.
What is the Price-to-Book ratio of Trevi Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Trevi Therapeutics Inc P/B ratio is 4.8957.
What is the 50-day moving average of Trevi Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Trevi Therapeutics Inc 50-day moving average is $7.46.
How many employess does Trevi Therapeutics Inc has?